Registration is now open for the 3rd Annual Biosimilars USA conference in New Jersey this November!
While biosimilars are not new in EMEA and few APAC countries (such as Korea and Japan), commercialization in the US has been extremely slow. Resistance from patients, defence from originators and unclear regulatory approval process all contributed to a slower start. While the first product, Zarxio, was approved in March 2015, the product did not actually come to market until Sept due to BPCIA - which Sandoz is filing this landmark case to the Supreme Court against originator Amgen.
At the same time, FDA is about to release the final guidelines of biosimilars immunogenicity assessment, and the first draft of interchangeability of biosimilars in 2016 - which will no doubts drive commercialization and more approvals.
As such, the 3rd Annual Biosimilars North America (Woodbridge Hotel, Iselin, New Jersey, USA, November 16-17, 2016) will provide timely discussion with case studies to reference to, and regulatory updates for participants to ensure both clinical and commercial success to replenish their pipelines!
This year's agenda will feature case studies from leading biosimilars developers, discussing how do they navigate through the regulatory and commercial environment. This is the only conference that delve into the whole value chain of biosimilars - from science to legal to marketing.
Elite Speaker Panel 2016 include:
- Edric Engert, Senior Vice President, Biosimilars, Teva Pharmaceuticals
- Gustavo Grampp, Ph.D., Director R&D Policy - Biosimilars, Amgen Inc.
- Hillel Cohen, Executive Director, Scientific Affairs, Sandoz
- Andrew Simpson, Scientific Director, Orygen Biotechnologia S/A
- Dr. Jianguo Yang, CEO, Abpro-China; Vice President, Abpro-US
- Daniel Alvarez, Senior Director, Asset Lead, Global Established Pharma, Pfizer Inc.
To see the full speaker line up and event programme visit : www.biosimilars-northamerica.com/mnt
In addition to the event, we have tailored two interactive pre-conference workshops:
A: Leveraging Successful Patient Recruitment & Retention Strategies in Biosimilars Research Led by Shazia Ahmad, Director, Patient & Physician Services, UBC - An Express Scripts Company
B: Biosimilars: Considerations for Optimizing Access and Price Led by: Mkaya Mwamburi, Vice President, HEOR/Evidence Generation, MKTX Market Access Solutions, LLC
For sponsorship opportunities please get in touch with Alia Malick: +44 (0) 20 7827 6168 or email: firstname.lastname@example.org
For more information or to register please visit: www.biosimilars-northamerica.com/mnt, alternatively contact Fateja Begum: +44 (0) 207 827 6184 or email: email@example.com